• Nasdaq hearings panel notified DNA X on Aug. 28, 2026 that it regained compliance with the $2.5 million stockholders’ equity rule.
• Securities remain at risk of delisting if the company fails to stay compliant with all Nasdaq listing rules through Nov. 18, 2026.
• Mandatory panel monitor runs until Aug. 28, 2027, tightening consequences for any renewed equity shortfall.
• A repeat breach would trigger a delisting determination with no option to submit a compliance plan or receive extra time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040845), on August 31, 2026, and is solely responsible for the information contained therein.